Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Am J Transplant. 2011 Dec 7;12(2):438–446. doi: 10.1111/j.1600-6143.2011.03857.x

Figure 2. Graft survival of lung transplant patients with high or low levels of BAL CXCL9 (A) or CXCL10 (B).

Figure 2

Analyte area under the curve was assessed for 40 patients over the first year postlung transplant. Patients were divided into high and low levels if they were above or below the median. Event free survival indicates freedom from diagnosis of BOS or histologic BO. p < 0.01 for CXCL9 and CXCL10 by log-rank test. N = 20 patients per group.